Plain-English translation of NCT06497361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of immunotherapy made from your own immune cells that have been engineered in the lab to target and control disease-causing cells. The study will evaluate whether this treatment is safe and effective for people with two serious autoimmune conditions — lupus kidney disease and IgG4-related disease — that have not responded well to standard medications. The researchers will start with smaller doses and gradually increase them to find the safest and most effective dose.
Some patients with lupus kidney disease and IgG4-related disease don't improve with the medications typically prescribed, leading to ongoing kidney damage and serious complications. This trial exists to test whether engineered immune cells can offer hope to patients who have exhausted standard treatment options.
You likely qualify if…
You likely don't qualify if…
You will first undergo screening blood tests and evaluations to confirm you qualify. If you are selected, doctors will collect some of your immune cells, which will be sent to a lab where they are engineered and grown into larger quantities. Once ready, you will receive an infusion of these engineered cells. You will then be closely monitored over time with regular blood tests and clinic visits to check whether the treatment is working and to watch for any side effects. The study is divided into two phases: first, researchers test different dose levels to find the safest effective dose, and then more patients receive that chosen dose to confirm its safety and benefits.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Tongji Hospital
Collaborators
Shenzhen Pregene Biopharma Co., Ltd.
Enrollment target
~30 participants
Started
July 2024
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lingli Dong
Tongji Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.